Advertisement
Skip to Content

Roche Holding AG ROG Stock Quote

| Rating as of

XSWX: ROG

Last close prices updated as of Feb 07, 2023, 5:30 PM CET | CHF
  • Last Close 283.9
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Blend
  • Day Range 282.95  –  285.50
  • Year Range 276.30  –  404.20
  • Market Cap 227.7647 Bil
  • Volume / Avg 1.6 Mil /  1.2 Mil
  • Price / Sales 3.68
  • Price / Book 9.02
  • Forward Div Yield 3.35%
  • Trailing Div Yield 3.27%

Morningstar‘s Stock Analysis ROG

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Roche: Double Hit From Lost COVID-19 Revenue and Biosimilars in 2023; Investors Taking Myopic View

Karen Andersen Sector Strategist

Analyst Note

| Karen Andersen |

After updating our model for Roche’s full-year 2022 financial performance, foreign exchange rates, and our new assumptions for the firm’s portfolio and pipeline, we’re slightly adjusting our fair value estimates to CHF 419/$57 (from CHF 428/$57). Roche continues to trade at a steep 35% discount to our fair value estimates, and we think the market underappreciates Roche’s long-term growth potential, putting too much emphasis on the upcoming COVID-19-related sales losses in 2023 as well as recent pipeline failures. Roche saw 2% constant currency growth (1% as reported) in 2022, as newer drug launches and underlying demand for the firm’s diagnostics countered pressure from biosimilar versions of older oncology drugs (CHF 1.9 billion headwind) as well as lower COVID-19-related revenue in both divisions (amounting to a roughly CHF 1 billion headwind). Incorporating an expected CHF 5 billion decline in COVID-19-related sales and CHF 1.6 billion decline from oncology biosimilars in 2023, management expects a low-single-digit decline in sales and core earnings per share in 2023 at constant currencies. Our updated forecast for 2023 is slightly more bearish, assuming a 3% top-line decline and 4.7% decline in core EPS for the year. That said, we think fundamental growth for the firm’s underlying business looks strong, with multiple trial readouts and launches that will continue to support Roche’s wide moat.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ROG

Company Profile ROG

Business Description

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Contact
Grenzacherstrasse 124
Basel, 4070, CHE
Industry Drug Manufacturers - General
Employees 103,613

Related Articles ROG

FAQs for Roche Holding AG Stock

Yes. ROG has a forward dividend yield of 3.35%. See ROG’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

ROG’s market cap is 227.76 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

ROG’s stock style is Large Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

ROG’s price/sales is 3.68.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

ROG’s price/forward earnings is 13.55.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

ROG’s price/book is 9.02.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See ROG’s valuation ratios compared to the Market Index.

ROG’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare ROG’s historical performance against its industry peers and the overall market.